Regenxbio Inc
RGNX10.330USD
+0.070+0.68%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
522.89MMarket Cap
LossP/E TTM
More Details of Regenxbio Inc Company
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Regenxbio Inc Info
Ticker SymbolRGNX
Company nameRegenxbio Inc
IPO dateSep 17, 2015
CEOSimpson (Curran M)
Number of employees353
Security typeOrdinary Share
Fiscal year-endSep 17
Address9804 Medical Center Drive
CityROCKVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20850
Phone12405528181
Websitehttps://regenxbio.com/
Ticker SymbolRGNX
IPO dateSep 17, 2015
CEOSimpson (Curran M)
Company Executives of Regenxbio Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
127.72K
+73749.00%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
121.60K
+105494.00%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
82.19K
+64609.00%
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-71824.00%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+7768.00%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+7768.00%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
19.05K
+7768.00%
Mr. Kenneth T. (Ken) Mills
Mr. Kenneth T. (Ken) Mills
Chairman of the Board
Chairman of the Board
--
--
Dr. A. N. (Jerry) Karabelas, Ph.D.
Dr. A. N. (Jerry) Karabelas, Ph.D.
Independent Director
Independent Director
--
--
Mr. Allan M. Fox, J.D.
Mr. Allan M. Fox, J.D.
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
127.72K
+73749.00%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
121.60K
+105494.00%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
82.19K
+64609.00%
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-71824.00%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+7768.00%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+7768.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Jan 14
Updated: Wed, Jan 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Redmile Group, LLC
9.27%
BlackRock Institutional Trust Company, N.A.
8.21%
The Vanguard Group, Inc.
6.67%
Fox (Allan Mark)
5.73%
JP Morgan Asset Management
5.16%
Other
64.96%
Shareholders
Shareholders
Proportion
Redmile Group, LLC
9.27%
BlackRock Institutional Trust Company, N.A.
8.21%
The Vanguard Group, Inc.
6.67%
Fox (Allan Mark)
5.73%
JP Morgan Asset Management
5.16%
Other
64.96%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
33.70%
Investment Advisor
31.87%
Research Firm
9.14%
Hedge Fund
8.86%
Individual Investor
8.29%
Private Equity
0.50%
Family Office
0.31%
Bank and Trust
0.25%
Pension Fund
0.11%
Other
6.96%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
409
42.96M
84.86%
-6.45M
2025Q3
403
44.05M
87.32%
-5.71M
2025Q2
421
48.19M
95.62%
-3.63M
2025Q1
446
48.46M
96.35%
-3.90M
2024Q4
444
48.16M
97.22%
-4.82M
2024Q3
444
49.64M
100.43%
-4.45M
2024Q2
437
49.30M
99.98%
-3.20M
2024Q1
451
48.23M
99.21%
+414.63K
2023Q4
436
43.62M
98.84%
-7.14M
2023Q3
439
43.73M
99.56%
-6.26M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Redmile Group, LLC
4.69M
9.27%
-82.33K
-1.72%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.16M
8.21%
-109.09K
-2.56%
Sep 30, 2025
The Vanguard Group, Inc.
3.34M
6.59%
-83.09K
-2.43%
Sep 30, 2025
Fox (Allan Mark)
2.90M
5.73%
+7.77K
+0.27%
May 30, 2025
JP Morgan Asset Management
2.61M
5.16%
-375.24K
-12.57%
Sep 30, 2025
State Street Investment Management (US)
1.98M
3.92%
+141.23K
+7.66%
Sep 30, 2025
Goldman Sachs & Company, Inc.
1.62M
3.2%
+15.37K
+0.96%
Sep 30, 2025
BlackRock Financial Management, Inc.
1.50M
2.97%
-226.30K
-13.07%
Sep 30, 2025
Morgan Stanley & Co. LLC
1.45M
2.85%
+700.19K
+94.00%
Sep 30, 2025
AQR Capital Management, LLC
1.29M
2.55%
+359.46K
+38.64%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
WisdomTree BioRevolution Fund
2.25%
iShares Neuroscience and Healthcare ETF
1.02%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
Global X Genomics & Biotechnology ETF
0.65%
JPMorgan Fundamental Data Science Small Core ETF
0.45%
ALPS Medical Breakthroughs ETF
0.27%
State Street SPDR S&P Biotech ETF
0.24%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
Fidelity Enhanced Small Cap ETF
0.12%
ProShares Ultra Nasdaq Biotechnology
0.08%
View more
WisdomTree BioRevolution Fund
Proportion2.25%
iShares Neuroscience and Healthcare ETF
Proportion1.02%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.85%
Global X Genomics & Biotechnology ETF
Proportion0.65%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.45%
ALPS Medical Breakthroughs ETF
Proportion0.27%
State Street SPDR S&P Biotech ETF
Proportion0.24%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.13%
Fidelity Enhanced Small Cap ETF
Proportion0.12%
ProShares Ultra Nasdaq Biotechnology
Proportion0.08%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
